Abra reports first COVID-19 death | Inquirer News

Abra reports first COVID-19 death

By: - Correspondent / @kquitasolINQ
/ 10:46 AM August 01, 2020

BAGUIO CITY – Abra has recorded its first coronavirus disease 2019 (COVID-19) death on Friday.

The 85-year old female patient from Danglas town succumbed to complications linked to COVID-19 Friday night at the Abra Provincial Hospital Isolation Unit, according to the Provincial Epidemiology Surveillance Unit of the Provincial Health Office.

The patient was stranded in Antipolo City when tight lockdown measures were imposed last March.

Article continues after this advertisement

She exhibited COVID-19 symptoms when she returned to Abra.  Her swab test result showed that she contracted the viral respiratory illness.

FEATURED STORIES

As of August 1, Abra has 9 active COVID-19 cases, although 10 other patients have recovered.

Individuals travelling to Abra will be required to undergo a rapid test and  present pertinent documents, such as a  Health Declaration Form,  medical certificate as well as a valid ID at the triage center of the province.

gsg
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: Abra, COVID-19

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.